# Palatin Technologies (stock symbol: PTN) Logo in transparent PNG and SVG formats

## Palatin Technologies Logo large

### Palatin Technologies Logo large Download PNG (41.59 KB)

![Palatin Technologies Logo large Download PNG (41.59 KB)](/img/orig/PTN_BIG-748db0b0.png)

### Palatin Technologies Logo large Download SVG (4.63 KB)

![Palatin Technologies Logo large Download SVG (4.63 KB)](/img/orig/PTN_BIG-cfb0451d.svg)

## Palatin Technologies Logo icon format

### Palatin Technologies Logo icon format Download PNG (42.01 KB)

![Palatin Technologies Logo icon format Download PNG (42.01 KB)](/img/orig/PTN-435b2aff.png)

### Palatin Technologies Logo icon format Download SVG (3.84 KB)

![Palatin Technologies Logo icon format Download SVG (3.84 KB)](/img/orig/PTN-e413813d.svg)

## Palatin Technologies Logo large for dark backgrounds

### Palatin Technologies Logo large for dark backgrounds Download PNG (25.65 KB)

![Palatin Technologies Logo large for dark backgrounds Download PNG (25.65 KB)](/img/orig/PTN_BIG.D-12b7f4ea.png)

### Palatin Technologies Logo large for dark backgrounds Download SVG (4.63 KB)

![Palatin Technologies Logo large for dark backgrounds Download SVG (4.63 KB)](/img/orig/PTN_BIG.D-08877da3.svg)

## Palatin Technologies Logo icon format for dark backgrounds

### Palatin Technologies Logo icon format for dark backgrounds Download PNG (41.58 KB)

![Palatin Technologies Logo icon format for dark backgrounds Download PNG (41.58 KB)](/img/orig/PTN.D-0768c122.png)

### Palatin Technologies Logo icon format for dark backgrounds Download SVG (3.85 KB)

![Palatin Technologies Logo icon format for dark backgrounds Download SVG (3.85 KB)](/img/orig/PTN.D-6aa1dd21.svg)

## About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

1. Website domain: palatin.com
2. Employees: 33
3. Marketcap: $25.42 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
